When a company beats profit expectations and raises its future outlook, it signals that the underlying business is stronger than the market previously thought. This positive surprise often attracts new buyers over the following weeks as analysts upgrade t

Verdict: a cash machine at a crossroads — wait for the RSI to confirm

The strongest point for this trade is real: Cardinal Health just posted fiscal 2026 revenue of $254.2B (up 14.2%), free cash flow of $4.5B (up 218.7%, in the top 1% of Health Care peers), and a 4% pop on the August 11 earnings beat per Yahoo Finance — the kind of cash-generative fundamentals that can attract multi-week institutional accumulation. The strongest point against is that this is a thin-margin distributor whose net margin slipped to 0.67% from 0.71%, whose equity is deeply negative (about negative $2.9B), and whose insiders were net open-market sellers of roughly $546K in the June 30, 2026 ownership reporting period — the opposite of management backing the post-earnings thesis. Critically, the momentum claim itself cannot be validated here: market-data coverage could not be verified within the retry window, so the entire argument rests on fundamentals and one 4% day. Tactically, the setup is close but not triggered — the RSI (14) reads about 35.7 and needs to cross above 40, while three of four entry conditions are in place and price sits about $0.10 above the EMA (50). A close below $220.18 support before the crossover would kill the setup; confirmed continuation above RSI 40 with no breach of $223.89 would flip this toward buying.

Trade now

CAH closed at $228.46, and the strategy's entry is close but not triggered. Three of four entry conditions are in place: the Stochastic (14) reads about 15.5 (needs below 40 — met), ADX (14) reads about 44.0 (needs above 20 — met), and price is essentially at the EMA (50) of $228.36 — only about $0.10 away, so that condition is near-met. The missing piece is the RSI (14): it reads about 35.7 and must cross above 40. Until that crossover prints, the correct action is to wait — do not front-run the signal. One scope note: the rule set could not be verified against market data within the retry window, so this analysis scores the live setup, not historical performance. Risk and reward are defined mechanically. Once triggered, the plan uses a 2% stop and a 4% profit target — a 2:1 reward-to-risk profile — plus a time exit at 60 trading bars. In price terms from the current close, the stop sits near $223.89 and the target near $237.60; the structural take-profit also flags the nearest resistance at $230, and the structural stop reference is support rank 2 at $213.58. If price instead breaks down through $220.18 (nearest support) before the RSI crossover occurs, treat the setup as stale and re-evaluate. Position sizing is fixed-risk at 2% of the account per trade, capped at 25% of the portfolio.

What supports the trade

The August 11, 2026 earnings report (per Yahoo Finance) is exactly the kind of event this thesis is built around: Cardinal Health beat profit estimates and its fiscal 2027 outlook topped forecasts, and the stock rose about 4% on the news. The fundamentals behind that beat are real. Fiscal year 2026 revenue came in at $254.2B, up 14.2% year over year — mid-pack growth for Health Care but enormous in absolute dollars, and diluted EPS of $7.23 grew 12.1% from the prior year. Net income jumped from $467M in the December half to $1.71B in the June half, a 267% improvement, showing the earnings acceleration is genuine rather than a one-off quarter. The cash story is the…

Scores

• Conviction score breakdown: 58
• Thesis support: 55
• Trade readiness: 60
• Risk quality: 48
• Fundamentals trend: 68

Watch items

• CAH — RSI (14)
• CAH — Close vs EMA (50)
• CAH — Stochastic (14)
• CAH — ADX (14)
• CAH — Nearest support
• CAH — Insider net open-market value
• CAH — Price
• CAH — Stochastic (14) below 40
• CAH — ADX (14) above 20
• CAH — RSI (14) crossed above 40